

First sales of ViewnVivo in the Chinese market

Highlights:

- **First sales of ViewnVivo in China with the purchase of two systems by Fudan University in Shanghai.**
- **Underlines Optiscan's solid progress with ViewnVivo commercialisation.**
- **Highlights the increasing acceptance of the unique imaging technology by the preclinical research community worldwide.**
- **Fudan University has agreed to work as a reference site and will facilitate continued exposure of ViewnVivo among the global preclinical research community.**
- **Optiscan expects further sales of ViewnVivo in China over the remainder of 2017 and beyond.**

Optiscan Imaging Limited (ASX:OIL; "Optiscan" or "The Company") is pleased to announce that it has secured its first sales of its ViewnVivo platform in China with the purchase of two systems by Fudan University in Shanghai.

ViewnVivo is Optiscan's endomicroscope system for Preclinical Research that promises to revolutionise *in vivo* imaging. It allows preclinical researchers to obtain cellular and sub-cellular images from living tissue in a living animal (*in vivo*) in real time. It also provides greater control and flexibility and provides images of higher resolution compared to other existing endomicroscope technologies.

The first sales of the product in China underlines Optiscan's solid progress with commercialisation of ViewnVivo. It also underlines the growing acceptance of the Optiscan technology by the preclinical research community worldwide.

Under the move, Fudan University has purchased two Optiscan ViewnVivo systems and has agreed to work with Optiscan as a reference site. The University will facilitate continued exposure and reinforcement of the value of ViewnVivo's flexible high-resolution *in vivo* imaging among the preclinical research community globally. Optiscan secured the Fudan University sales through a competitive public tender process and shipment of the product is expected in around four weeks.

Fudan University is ranked among the top five universities in China. It currently has 14,100 undergraduates and associate degree candidates, 14,800 graduates including 3,000 foreign degree candidates, 2,700 staff and 3,100 full-time teaching faculty members.

"These sales of ViewnVivo to Fudan University shows our solid progress with commercialising this unique platform technology. We are continuing to rapidly progress the commercialisation process in the Chinese market with a number of leading Chinese research institutes expecting to finalise their purchase agreements over the near term," said Optiscan Chief Executive Officer Archie Fraser.

"Additionally, our direct activity with distributors and potential customers in China indicates that we should receive more orders in 2017 and beyond."

Corporate Enquiries:

Archie Fraser
Chief Executive Officer
Optiscan Imaging Limited
E: afrazer@optiscan.com

Media Enquiries:

Ruth Thomas
Media + Capital Partners
E: ruth.thomas@mcpartners.com.au
M: 0413 456 491

About Optiscan

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes and is now a global leader in the development and application of microscopic imaging technologies for preclinical research and medical markets. With the high cost of curative medicine, an opportunity exists for Optiscan's technology to be used globally to reduce costs and be used as a key tool for the early detection of disease, the effective treatment of disease and the improvement of treatment outcomes.